C.R. Bard, Inc. (BCR) Stake Reduced by UMB Bank N A MO
UMB Bank N A MO cut its stake in C.R. Bard, Inc. (NYSE:BCR) by 12.3% during the second quarter, Holdings Channel reports. The fund owned 6,354 shares of the medical instruments supplier’s stock after selling 895 shares during the period. UMB Bank N A MO’s holdings in C.R. Bard were worth $2,008,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Parallel Advisors LLC increased its position in C.R. Bard by 283.8% in the first quarter. Parallel Advisors LLC now owns 499 shares of the medical instruments supplier’s stock valued at $153,000 after buying an additional 369 shares during the last quarter. Cribstone Capital Management LLC acquired a new position in C.R. Bard during the first quarter valued at $130,000. Whittier Trust Co. increased its position in C.R. Bard by 7.7% in the first quarter. Whittier Trust Co. now owns 591 shares of the medical instruments supplier’s stock valued at $147,000 after buying an additional 42 shares during the last quarter. ClariVest Asset Management LLC acquired a new position in C.R. Bard during the first quarter valued at $148,000. Finally, SRS Capital Advisors Inc. increased its position in C.R. Bard by 0.7% in the first quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock valued at $148,000 after buying an additional 4 shares during the last quarter. Institutional investors and hedge funds own 85.32% of the company’s stock.
C.R. Bard, Inc. (NYSE BCR) opened at 319.75 on Friday. The stock’s 50 day moving average price is $319.00 and its 200-day moving average price is $283.44. The company has a market capitalization of $23.24 billion, a P/E ratio of 41.98 and a beta of 0.59. C.R. Bard, Inc. has a 52-week low of $203.63 and a 52-week high of $323.27.
C.R. Bard (NYSE:BCR) last released its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.84 by $0.08. The company had revenue of $979.70 million for the quarter, compared to analyst estimates of $976.53 million. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.54 earnings per share. Analysts predict that C.R. Bard, Inc. will post $11.84 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, August 4th. Shareholders of record on Monday, July 24th were paid a dividend of $0.26 per share. This represents a $1.04 dividend on an annualized basis and a yield of 0.33%. The ex-dividend date of this dividend was Thursday, July 20th. C.R. Bard’s dividend payout ratio (DPR) is currently 13.67%.
ILLEGAL ACTIVITY WARNING: This story was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://theolympiareport.com/2017/08/12/c-r-bard-inc-bcr-stake-reduced-by-umb-bank-n-a-mo.html.
Several research analysts have weighed in on the company. BidaskClub downgraded C.R. Bard from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Jefferies Group LLC restated a “hold” rating on shares of C.R. Bard in a research note on Thursday, August 3rd. Raymond James Financial, Inc. restated a “market perform” rating and issued a $265.00 price target on shares of C.R. Bard in a research note on Tuesday, April 25th. Zacks Investment Research upgraded C.R. Bard from a “hold” rating to a “buy” rating and set a $360.00 price target for the company in a research note on Monday, July 31st. Finally, BMO Capital Markets restated a “hold” rating and issued a $317.00 price target on shares of C.R. Bard in a research note on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $285.67.
In other C.R. Bard news, insider John P. Groetelaars sold 23,687 shares of the business’s stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the transaction, the insider now owns 31,445 shares of the company’s stock, valued at $10,022,464.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.80% of the company’s stock.
About C.R. Bard
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.